107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 46

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

Background

Breast cancer brain metastases (BCBM) contribute to substantial morbidity and mortality in patients with HER2-positive (HER2+) metastatic breast cancer. The central nervous system (CNS) is a common site of recurrence in patients with HER2+ breast cancer, and there is an ongoing need for safe and effective treatments. Neratinib, an oral, irreversible pan-HER tyrosine kinase inhibitor, is FDA-approved for the extended adjuvant treatment of early-stage HER2+ breast cancer and in combination with capecitabine for HER2+ advanced or metastatic breast cancer. We summarize prospective data of neratinib-based combinations in HER2+ BCBM.

Materials and Methods

We conducted a literature review of neratinib combinations for HER2+ BCBM, focusing on prospective trials reporting CNS outcomes. CNS-specific data were extracted from studies restricted to patients with untreated/active brain metastases (phase 2 TBCRC 022 [NCT01494662]) or asymptomatic/stable brain metastases (phase 3 NALA [NCT01808573] and phase 2 NEfERT-T [NCT00915018]). TBCRC 022, a dedicated HER2+ BCBM trial, assessed neratinib combinations in patients with no prior lapatinib (cohort 3A; neratinib plus capecitabine) or with prior lapatinib (cohort 3B; neratinib plus capecitabine), in patients with previously untreated brain metastases (cohort 4A; neratinib plus T-DM1), and in patients progressing after CNS-directed therapies with no prior T-DM1 (cohort 4B; neratinib plus T-DM1) or in patients with prior T-DM1 (cohort 4C; neratinib plus T-DM1). Also available were descriptive CNS outcomes for (1) patients with baseline CNS metastases previously treated with HER2-directed therapy in NALA (neratinib plus capecitabine vs lapatinib plus capecitabine) and (2) patients who are metastatic treatment-naive in NEfERT-T (neratinib plus paclitaxel vs trastuzumab plus paclitaxel). End points included CNS objective response rate (CNS-ORR) per composite/volumetric (TBCRC 022) or RECIST (NALA and NEfERT-T) (assessed locally or centrally), or ORR per Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM; assessed centrally). Cumulative 1-year incidence ofintervention for CNS disease or incidence of progressive CNS disease were reported for the NALA CNS subgroup.

Results

The analysis includes 212 patients: 93 with untreated/active BCBM from TBCRC 022; 101 (16.3% of ITT) from NALA; and 18 (3.8% of ITT) from NEfERT-T. No patients had received prior tucatinib and only 2 patients in TBCRC 022 cohort 4 had received prior trastuzumab deruxtecan.Across all 3 studies, 131 patients had measurable/target CNS lesions at baseline and were evaluable for CNS-ORR (TBCRC 022: n = 49 in cohort 3 and n = 44 in cohort 4; NALA: n = 32; NEfERT-T: n = 6). In TBCRC 022, CNS-ORRs were 49% (18/37 in cohort 3A; neratinib plus capecitabine), 33% (4/12 in cohort 3B; neratinib plus capecitabine), 50% (3/6 in cohort 4A; neratinib plus T-DM1), 29% (5/17 in cohort 4B; neratinib plus T-DM1), and 24% (5/21 in cohort 4C; neratinib plus T-DM1). In NALA, CNS-ORRs were 26% (5/19 pts; neratinib plus capecitabine) vs 15% (2/13; lapatinib plus capecitabine). In NEfERT-T, CNS-ORRs were 100% (3/3; neratinib plus paclitaxel) vs 33% (1/3; trastuzumab plus paclitaxel). In TBCRC 022, RANO-BM ORRs were 24% (9/37; cohort 3A), 17% (2/1; cohort 3B), 33% (2/6; cohort 4A), 35% (6/17; cohort 4B), and 29% (6/21; cohort 4C). In the NALA CNS subgroup (n = 101), 1-year cumulative incidence of intervention for CNS disease was 26% for neratinib plus capecitabine vs 36% for lapatinib plus capecitabine, and 1-year cumulative incidence of progressive CNS disease was 26% (neratinib plus capecitabine) vs 42% (lapatinib plus capecitabine). Diarrhea was the most common grade 3 or higher toxicity.

Conclusion

Data from prospective trials of neratinib-based combinations show consistent intracranial activity across various treatment settings in untreated/active and asymptomatic/stable HER2+ BCBM. Clinical guidelines and real-world analyses further support the use of neratinib combinations for HER2+ BCBM. Notably, neratinib plus T-DM1 had intracranial efficacy in patients with previously untreated brain metastases and patients who had undergone multiple local CNS-directed and/or systemic therapies, including prior T-DM1. In addition to the established CNS activity of tucatinib and trastuzumab deruxtecan, the combination of neratinib with other FDA-approved drugs represents a promising approach to the treatment of HER2+ BCBM in clinical practice, although the optimal sequence of treatments is not known.

Articles in this issue

39 Development and Validation of a Questionnaire to Assess Motivation and Satisfaction in Mastectomy Patients With or Without Reconstruction
39 Development and Validation of a Questionnaire to Assess Motivation and Satisfaction in Mastectomy Patients With or Without Reconstruction
40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data
40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data
41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists
41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists
42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US
42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US
TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery
45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status
48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status
49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval
49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval
52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer
52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer
53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy
53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy
54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial
54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial
55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?
55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?
56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?
56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?
57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers
57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers
Recent Videos
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
2 experts in this video
2 experts in this video
Related Content